On (b)(6) 2020, the pre-scheduled stimulator pull, it was discovered that the trial stimulator had migrated downward from top of 8th thoracic vertebrae to the top of 5th thoracic vertebrae.The implanting clinician had to perform an incision to obtain the tail end of the stimulator to pull it out.The implanting clinician took cultures of the wound (as the incision was red and irritated) after successfully removing the trial stimulator.On (b)(6) 2020, the patient had a follow-up appointment with the implanting clinician.During this follow-up, the cultures were received and no infection was present.The cr followed up with patient and the patient stated that is doing well and is not reporting irritation or further issues after the removal of the trial leads.The patient is planning to move forward with a permanent implant procedure.On (b)(6), 2020, the cr reported that the implanting clinician was not compliant with the ifu (document # 05-00347, revision 14, page 22, section: securing the trial lead).The implanting clinician reported using mastisol and steristrips to secure the stimulators.
|
Stimwave quality has investigated the details for a reported migration/skin irritation, submitted to the stimwave complaint system on (b)(6) 2020, by clinical representative (cr), in the united states.Cr became aware of this issue (b)(6) 2020.
|